# Leucine-rich repeats and immunoglobulin-like domains 3 suppresses hypoxia-induced vasculogenic mimicry in glioma by promoting the ubiquitination and degradation of Snail2

**Authors:** Yang Guo, Dongsheng Guo, Ran Xu, Wenjin Qiu, Chenghao Peng

PMC · DOI: 10.1016/j.cstres.2026.100152 · Cell Stress & Chaperones · 2026-02-13

## TL;DR

LRIG3 suppresses hypoxia-induced vasculogenic mimicry in glioma by promoting the breakdown of Snail2 through ubiquitination.

## Contribution

LRIG3's novel role in suppressing hypoxia-induced VM via Snail2 ubiquitination is identified.

## Key findings

- LRIG3 expression inversely correlates with VM density in hypoxic glioma regions.
- LRIG3 overexpression inhibits glioma cell invasion and tube formation under hypoxia.
- LRIG3 promotes Snail2 ubiquitination and proteasomal degradation, suppressing VM.

## Abstract

Leucine-rich repeats and immunoglobulin-like domains 3 (LRIG3) functions as a tumor suppressor in glioma. Although our previous study demonstrated that LRIG3 inhibited angiogenesis via the PI3K/AKT/VEGFA pathway under normoxia, its impact on glioma vascularization under hypoxia remains elusive. Vasculogenic mimicry (VM), an alternative form of neovascularization, plays a pivotal role in glioma progression, particularly within hypoxic tumor microenvironments. This study aimed to investigate the effects of LRIG3 on hypoxia-induced VM in glioma and to elucidate the underlying molecular mechanisms.

The effects of LRIG3 on VM were evaluated in vitro using tube formation and 3D spheroid invasion assays. Histological analysis of intracranial xenografts and glioblastoma specimens was performed to assess LRIG3's impact on glioma vascularization in vivo. The underlying mechanisms were investigated using western blot, quantitative real-time PCR (qRT-PCR), and ubiquitination assays.

LRIG3 expression was inversely correlated with VM density in the central hypoxic regions of both xenografts and glioblastoma specimens. Under hypoxia, LRIG3 overexpression inhibited the invasion and tube formation capacities of glioma cells, whereas its knockdown promoted these activities. Mechanistically, LRIG3 suppressed VM phenotypes by downregulating Snail2 at the post-translational level, rather than affecting VEGFA. LRIG3 promoted the ubiquitination of Snail2, leading to its proteasomal degradation and destabilization under hypoxia.

LRIG3 inhibits hypoxia-induced VM in glioma by facilitating the proteasomal degradation of Snail2 via ubiquitination.

## Linked entities

- **Genes:** LRIG3 (leucine rich repeats and immunoglobulin like domains 3) [NCBI Gene 121227], SNAI2 (snail family transcriptional repressor 2) [NCBI Gene 6591], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207]
- **Diseases:** glioma (MONDO:0021042), glioblastoma (MONDO:0018177)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847], SNAI2 (snail family transcriptional repressor 2) [NCBI Gene 6591] {aka SLUG, SLUGH, SLUGH1, SNAIL2, WS2D}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, ZEB2 (zinc finger E-box binding homeobox 2) [NCBI Gene 9839] {aka HSPC082, SIP-1, SIP1, SMADIP1, ZFHX1B}, CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CD34 (CD34 molecule) [NCBI Gene 947], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, LRIG1 (leucine rich repeats and immunoglobulin like domains 1) [NCBI Gene 26018] {aka LIG-1, LIG1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, LRIG3 (leucine rich repeats and immunoglobulin like domains 3) [NCBI Gene 121227], SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}
- **Diseases:** cancers (MESH:D009369), VM (MESH:D018783), weight loss (MESH:D015431), metastasis (MESH:D009362), Glioma (MESH:D005910), colorectal cancer (MESH:D015179), necrotic (MESH:D009336), neurological (MESH:D009461), hypoxia (MESH:D000860), brain tumor (MESH:D001932), GBM (MESH:D005909), hypoxic (MESH:D002534), tumorigenesis (MESH:D063646)
- **Chemicals:** N2 (MESH:D009584), streptomycin (MESH:D013307), paraffin (MESH:D010232), Dulbecco's modified eagle's medium (-), penicillin (MESH:D010406), O2 (MESH:D010100), CHX (MESH:D003513), bevacizumab (MESH:D000068258), CoCl2 (MESH:C018021), CO2 (MESH:D002245), paraformaldehyde (MESH:C003043), MG132 (MESH:C072553)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Mycoplasma (genus) [taxon 2093]
- **Cell lines:** LN229 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0393), U251 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12966913/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966913/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12966913/full.md

---
Source: https://tomesphere.com/paper/PMC12966913